ARWR
NASDAQ · Biotechnology
Arrowhead Pharmaceuticals In
$58.16
+0.70 (+1.22%)
Financial Highlights (FY 2026)
Revenue
871.57M
Net Income
-1,714,711
Gross Margin
100.0%
Profit Margin
-0.2%
Rev Growth
+50.5%
D/E Ratio
1.34
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 59.1% | 59.1% |
| Operating Margin | 11.9% | 10.7% | -3.5% | -3.7% |
| Profit Margin | -0.2% | -0.2% | -3.8% | -4.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 871.57M | 579.04M | 3.64B | 3.79B |
| Gross Profit | 871.57M | 579.04M | 2.15B | 2.24B |
| Operating Income | 103.37M | 61.81M | -125,527,371 | -138,793,913 |
| Net Income | -1,714,711 | -1,025,272 | -138,687,526 | -172,834,954 |
| Gross Margin | 100.0% | 100.0% | 59.1% | 59.1% |
| Operating Margin | 11.9% | 10.7% | -3.5% | -3.7% |
| Profit Margin | -0.2% | -0.2% | -3.8% | -4.6% |
| Rev Growth | +50.5% | +50.5% | +9.5% | +21.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 2.34B | 2.34B | 1.64B | 1.56B |
| Total Equity | 1.75B | 1.75B | 3.73B | 3.62B |
| D/E Ratio | 1.34 | 1.34 | 0.44 | 0.43 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 128.48M | 81.09M | -183,881,108 | -178,755,728 |
| Free Cash Flow | — | — | -98,110,953 | -68,672,704 |